<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">In conclusion, COVID-19 patients undergoing treatment with LPV/r are exposed to having a high prevalence of potential interactions, with age (&gt;65), admission to the ICU, previous respiratory disease and psychiatric disorders, dyslipidaemia and the number of drugs prescribed behaving as associated risk factors. Knowledge of the potential interactions profile in a COVID-19 patient receiving LPV/r and his/her adequate treatment can improve the safety and effectiveness of treatments. Collaboration between hospital and clinical pharmacists is essential for the comprehensive approach and treatment of the COVID 19 pandemic.</p>
